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Background: Pseudomonas aeruginosa is an opportunistic pathogen that significantly increases morbidity and
mortality in nosocomial infections and cystic fibrosis patients. Its pathogenicity especially relies on the production
of virulence factors or resistances to many antibiotics. Since multiplication of antibiotic resistance can lead to
therapeutic impasses, it becomes necessary to develop new tools for fighting P. aeruginosa infections. The use of
probiotics is one of the ways currently being explored. Probiotics are microorganisms that exert a positive effect on
the host’s health and some of them are known to possess antibacterial activities. Since most of their effects have
been shown in the digestive tract, experimental data compatible with the respiratory environment are strongly
needed. The main goal of this study was then to test the capacity of lactobacilli to inhibit major virulence factors
(elastolytic activity and biofilm formation) associated with P. aeruginosa pathogenicity.
Results: Sixty-seven lactobacilli were isolated from the oral cavities of healthy volunteers. These isolates together
with 20 lactobacilli isolated from raw milks, were tested for their capacity to decrease biofilm formation and activity
of the elastase produced by P. aeruginosa PAO1. Ten isolates, particularly efficient, were accurately identified using a
polyphasic approach (API 50 CHL, mass-spectrometry and 16S/rpoA/pheS genes sequencing) and typed by pulsed-field
gel electrophoresis (PFGE). The 8 remaining strains belonging to the L. fermentum (6), L. zeae (1) and L. paracasei
(1) species were sensitive to all antibiotics tested with the exception of the intrinsic resistance to vancomycin.
The strains were all able to grow in artificial saliva.
Conclusion: Eight strains belonging to L. fermentum, L. zeae and L. paracasei species harbouring anti-elastase and
anti-biofilm properties are potential probiotics for fighting P. aeruginosa pulmonary infections. However, further
studies are needed in order to test their innocuity and their capacity to behave such as an oropharyngeal barrier
against Pseudomonas aeruginosa colonisation in vivo.
Keywords: Pseudomonas aeruginosa, Lactobacillus, Probiotics, Organic acids, Biofilm formation, Elastolytic activityBackground
Pseudomonas aeruginosa is one of the most common
pathogens responsible for acute respiratory infections
in ventilated or immunocompromised patients, and for
chronic respiratory infections in cystic fibrosis (CF) pa-
tients. Between 1975 and 2003, the frequency of hospital-
acquired pneumonia caused by P. aeruginosa increased
from 9.6% to 18.1%, this pathogen thus becoming the
main cause of acute respiratory infections [1]. Mortality* Correspondence: rozenn.leberre@chu-brest.fr
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unless otherwise stated.rates in ventilator-associated pneumonia caused by P.
aeruginosa range from 42.1 to 87% [2]. This bacteria is
also associated with over 80% of the morbidity and
mortality rates in CF patients [3]. These features may be
explained by the wide range of both cellular associated and
extracellular virulence factors involved in the pathogenesis
of P. aeruginosa pneumonia [4,5]. Indeed, P. aeruginosa
is endowed with remarkable virulence factors like lipo-
polysaccharide, type III secretion system, pyocyanin and
elastase. Moreover, it is intrinsically resistant to a large
number of antibiotics and can acquire resistances to many
others. P. aeruginosa may also form biofilms that protect
it from the host immune system, while decreasing antibi-
otics accessibility and increasing the difficulties of eradica-
tion in CF patients particularly [6]. Therapies based on theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Preliminary identification (MALDI-TOF analyses)
of newly isolated oral lactobacilli
Lactobacillus groups* Species** Isolates
L. reuteri L. reuteri 1
L. fermentum 30
L. vaginalis 3
L. casei L. zeae/casei 5
L. rhamnosus 6
L. paracasei 10
L. salivarius L. salivarius 4
L. plantarum L. plantarum 1
*According to Felis and Dellaglio [14], **MALDI-ToF scores above 1.8.
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http://www.biomedcentral.com/1471-2180/14/107exclusive use of antibiotics may then lead to therapeutic
impasses and it is necessary to find new therapeutic
options to fight P. aeruginosa pulmonary infections.
In this context, the use of probiotic bacteria, either as
prophylactic agents for preventing or delaying pulmonary
colonisation with P. aeruginosa, or eventually as thera-
peutic tool to fight P. aeruginosa infections, seems to be
particularly attractive.
The emergence of the microbiota concept, with the
accumulation of evidences that human associated micro-
biota play a major role in health and disease [7,8],
induced a profound modification in the perception of
probiotics. For long confined to the gastrointestinal tract,
where most of their positive effects have been described
[9], they are now covering a much broader domain of ap-
plications. Evidence is emerging that probiotics may have
a primordial role in health of the oral cavity [10] or in
preventing mechanically ventilated patients from ventila-
tor associated pneumonia. Several randomized controlled
trials directly exploring the role of probiotics in preventing
ventilator-associated pneumonia were published [11,12].
Even if the conclusions are controversial, probably be-
cause of the heterogeneity of the used probiotic strains, of
the mode of administration, of the clinical situations and
of the primary endpoint, this strategy seems promising.
The lack of rational work for the selection of probiotic
strains adapted to the respiratory ecosystem may be also
one of the reasons explaining the poor results obtained
in certain studies.
In this context, the main objective of this work was
the screening for putative probiotic strains active against
P. aeruginosa. Eighty-seven lactobacilli isolates, isolated
from the oral cavity or raw milk, were tested for their
capacity to inhibit elastolytic activity and biofilm forma-
tion, two main virulence factors of P. aeruginosa. In a
second step, the most active isolates were characterized
with molecular and phenotypic methods, and their anti-
biotic resistance and growth capacity in artificial saliva
were checked.
Results
Isolation and identification of oral lactobacilli
Sixty-seven colonies were isolated from the oral cav-
ities of 23 healthy volunteers. Among them, 7 isolates
were assigned at the genus level only (Lactobacillus)
by MALDI-TOF spectrometry analyses with scores
below 1.8, whereas the majority (60 isolates) were
assigned at the species level with scores above 1.8.
They belonged to 9 Lactobacillus species (Table 1), with a
strong representativeness of the Lactobacillus reuteri and
Lactobacillus casei groups with respectively 40 (with a
predominance of L. fermentum) and 21 isolates (with
a predominance of L. paracasei). The isolation and
characterization strategies of bacterial isolates are shownin Figure 1. These 67 isolates were pooled with 20
lactobacilli from a collection of bacteria isolated from
raw milks [13].
Effects of pH and acids on P. aeruginosa growth
P. aeruginosa strains are known to be sensitive to or-
ganic acids [15,16]. Since Lactobacillus spp. produce
lactic and acetic acids that inhibit the growth of many
bacteria through their undissociated forms at low pH,
the sensitivity of P. aeruginosa PAO1 was tested toward
both of them at different pH. P. aeruginosa PAO1 growth
was monitored in LB broth by measuring OD595nm values
at four pH (7, 6, 5 or 4), in presence (50 or 100 mM) or
absence of lactic acid. These results are presented in
Table 2. P. aeruginosa was sensitive to the pH decrease
with a pronounced growth inhibition at pH 5 and 4
(p < 0.0001). However, no specific effect of lactic acid
was observed (p = 0.21). The addition of acetic acid
induced different effects (Table 2). As observed pre-
viously, the pH induced a significant decrease of P.
aeruginosa (p < 0.0001), but in that case the addition
of acetic acid induced a significant reduction of P.
aeruginosa growth at pH 6 (from 50 mM of acetic acid
and higher) and at pH 5 (from 25 mM of acetic acid and
higher). No specific effect of acetic acid was detected on
P. aeruginosa at pH 4 (no growth) nor at pH 7 (growth),
whatever its concentration.
Effects of lactobacilli isolates on biofilm formation
Eighty-seven Lactobacillus isolates (67 from the oral cavity
and 20 from raw milk) were tested for their capacity to in-
hibit biofilm formation by P. aeruginosa PAO1 (Table 3).
As compared with the positive control (P. aeruginosa
PAO1 alone), only five isolates from the oral cavity signifi-
cantly (p < 0.05) reduced the amount of biofilm formation
after 7 h of co-incubation with P. aeruginosa PAO1 at
37°C in BHI broth (Table 3). The four L. fermentum
isolates ES.A.2, ES.F.115, ES.A.1a and ES.A.6a induced
a biofilm reduction of 3, 7, 10 and 11% respectively,
whereas L. paracasei ES.D.88 induced a reduction of
Growth of lactobacilli in artificial
saliva
n = 8 strains 
Selected strains
3 strains active against biofilm formation
5 strains active against elastolytic activity
Tested isolates
67 isolates from oral cavities of healthy volunteers
20 isolates from raw milks 
Biofilm assays 
5 active isolates 
Elastase assays 
5 active isolates 
Identification of isolates 
PCR sequencingon 16S RNA and rpoA genes 
API 50 CHL
Antibiotic resistance
n = 8 strains 
Clonality of isolates
Pulsed Field Gel Electrophoresis
n = 8 strains 
67 isolates from oral cavities 
Identification by MALDI-ToF mass spectrometry
Figure 1 Flow-chart of the strains selection strategy.
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ranging from 0.6 to 1 unit during the 7 h of co-incubation,
no growth inhibition of P. aeruginosa was observed.
Effects of lactobacilli isolates on elastolytic activity
The same eighty-seven isolates were tested for their cap-
acity to inhibit the elastolytic activity of P. aeruginosa
PAO1. Only five of them significantly (p < 0.001) reduced
the activity of elastase after 22 h of co-incubation with
P. aeruginosa PAO1 at 37°C in BHI broth, as compared
with the positive control (P. aeruginosa PAO1 alone)
(Table 3). Among them, 4 strains (K.C6.3.1D, K.V9.3.2B,
K.V9.3.2C and K.C6.3.1E) were L. fermentum isolated
from raw milk. They respectively reduced by 37%, 38%,38% and 47% the elastolytic activity of P. aeruginosa.
Only one strain isolated from the oral cavity (L. zeae
Od.76), significantly reduced (minus 36%) the elastolytic
activity. When grown in presence of lactobacilli during
22 h and despite a pH decrease ranging from 0.9 to 1.2
units of the BHI medium (pH 7.4), no inhibition of P.
aeruginosa growth was observed.
Formal identification of lactobacilli active against
P. aeruginosa
Once several isolates were shown to be active against P.
aeruginosa PAO1, their identity was confirmed by 16S
rRNA and rpoA genes sequencing, and API 50 CHL
(Table 4, Additional file 1). Two isolates (ES.D.88 and
Table 2 In vitro effects of pH, lactic and acetic acids on Pseudomonas aeruginosa PAO1 growth
Acid concentrations (mM) OD595nm of P. aeruginosa at different pH and acid concentrations*
Lactic acid pH 7 pH 6 pH 5 pH 4
0 0.60 ± 0.03 0.62 ± 0.01 0.43 ± 0.02 0.01 ± 0.00
50 0.74 ± 0.06 0.81 ± 0.11 0.47 ± 0.19 0.12 ± 0.01
100 0.65 ± 0.02 0.65 ± 0.02 0.23 ± 0.07 0.12 ± 0.01
Acetic acid pH 7 pH 6 pH 5 pH 4
0 0.60 ± 0.03 0.62 ± 0.01 0.43 ± 0.02 0.01 ± 0.00
12.5 0.70 ± 0.06 0.58 ± 0.02 0.38 ± 0.27 0.12 ± 0.01
25 0.63 ± 0.06 0.65 ± 0.09 0.11 ± 0.01 0.12 ± 0.00
50 0.56 ± 0.02 0.26 ± 0.07 0.11 ± 0.01 0.12 ± 0.01
100 0.77 ± 0.14 0.10 ± 0.01 0.11 ± 0.01 0.13 ± 0.01
*Each value is the mean of triplicates ± SD (ANCOVA), P. aeruginosa was incubated in BHI medium for 22 h in presence of different acid concentrations (acetic,
lactic acid or HCl).
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ively. In the last case, it was not possible to formally dis-
tinguish between the two closely related L. zeae and L.
casei species by sequencing 16S RNA and rpoA genes only.
The sequencing of pheS gene (Genbank accession num-
ber: KJ402364) was then necessary to formally assigned
the Od.76 strain to the L. zeae species. The eight other
active isolates (ES.A.1a, ES.A.2, ES.A.6a, ES.F.115, K.
C6.3.1D, K.C6.3.1E, K.V9.3.2B and K.V9.3.2C) were shown
to belong to L. fermentum. A pulsed-field gel electrophor-
esis (PFGE) showed that ES.A.1a, ES.A.2 and ES.A.6a were
clonal strains (data not shown). ES.A.2 was then the only
one kept for the last tests. The API 50 CHL gallery con-
firmed these results for all strains but one, L. zeae Od.76,
since this method is not designed to identify L. casei
nor L. zeae.Antibiotics sensitivity of lactobacilli
All the strains were resistant to vancomycin, as expected
for lactobacilli. No other resistance was detected against
the 9 other antibiotics for any of the tested strains (ampi-
cillin, vancomycin, gentamicin, kanamycin, streptomycin,Table 3 In vitro relative effects of lactobacilli isolates
against biofilm formation and elastolytic activity of
Pseudomonas aeruginosa PAO1
Biofilm formation* Elastolytic activity*
Control 100% Control 100%
L. fermentum ES.A.2 95% L. fermentum K.C6.3.1D 63%
L. fermentum ES.F.115 93% L. zeae Od.76 64%
L. fermentum ES.A.6a 88% L. fermentum K.V9.3.2B 62%
L. fermentum ES.A.1a 88% L. fermentum K.V9.3.2C 62%
L. paracasei ES.D.88 84% L. fermentum K.C6.3.1E 53%
*Results are expressed as a percentage of biofilm formation or elastolytic activity
related to control (P. aeruginosa PAO1 without lactobacilli). Only significantly
active strains compared to control are displayed (LSD test, p < 0.05 for biofilm
formation and p < 0.001 for elastolytic activity).erythromycin, clindamycin, quinupristin + dalfopristin,
tetracycline, chloramphenicol).
Lactobacilli growth and acidification properties in
artificial saliva
All the strains showed a good capacity to grow in artificial
saliva with final concentrations after 48 h of incubation at
37°C comprised between 1.8 × 106 and 9.3 × 107 CFU/ml
(Figure 2). Whatever the tested strain, no acidification oc-
curred during the first 12 h (pH 7.14 ± 0.06) (Figure 3).
The pH of artificial saliva however differed between
tested strains after 24 h of incubation with a clear distinc-
tion between two groups. The first group (L. fermentum
K.V9.3.2B, K.V9.3.2C, ES.A.2, and ES.F.115 and L. paraca-
sei ES.D.88) was poorly acidifying with a decrease of 0.65 ±
0.31 pH units, whereas the second one (L. fermentum K.
C6.3.1D, K.C6.3.1E and L. zeae Od.76) induced a much
higher pH decrease with a diminution of 2.45 ± 0.30 units.
However, after 36 h of incubation, the two facultative
heterofermentative strains L. paracasei ES.D.88 and L.
zeae Od.76 induced the highest pH decrease (minus
3.28 ± 0.36 pH units).
Discussion
P. aeruginosa is an opportunistic pathogen in patients
with significant underlying diseases. It is one of the most
common causes of hospital-acquired pneumonia, espe-
cially in mechanically ventilated patients, in whom it
leads to a high mortality rate [2,17]. Moreover, chronic
airway inflammation with recurrent P. aeruginosa infec-
tions is the major cause of morbidity and mortality in
patients with cystic fibrosis [18]. High incidence, infec-
tion severity and increasing resistance characterizing P.
aeruginosa infections highlight the need for new thera-
peutic options. In that context, different attempts have
been made to use probiotic bacteria for fighting P. aeru-
ginosa pulmonary infections [19]. Lactobacilli are non-
pathogenic bacteria closely associated with the human
Table 4 Species assignation of Lactobacillus isolates based on MALDI-TOF analyses, 16S RNA and rpoA genes
sequencing
Strain Mass spectrometry 16S RNA gene sequencing rpoA gene sequencing API 50 CHL
Identification Score* Identification NCBI accession number(GenBank) Identification
NCBI accession number
(GenBank) Identification Score
ES.A.2 L. fermentum 1.916 L. fermentum [KC762296] L. fermentum [KC861367] L. fermentum 96.3%
ES.D.88 L. paracasei 2.458 L. casei group [KC762297] L. paracasei [KC861369] L. paracasei 98.4%
ES.F.115 L. fermentum 2.21 L. fermentum [KC762298] L. fermentum [KC861368] L. fermentum 98.5%
Od.76***
L. zeae 2.089
L. casei group [KC762299] L. zeae/casei [KC861370] - ** - **
L. casei 2.043
K.C6.3.1D L. fermentum 2.18 L. fermentum [KC762300] L. fermentum [KC861371] L. fermentum 99.7%
K.C6.3.1E L. fermentum 2.109 L. fermentum [KC762301] L. fermentum [KC861372] L. fermentum 99.7%
K.V9.3.2B L. fermentum 2.163 L. fermentum [KC762302] L. fermentum [KC861373] L. fermentum 99.7%
K.V9.3.2C L. fermentum 2.223 L. fermentum [KC762303] L. fermentum [KC861374] L. fermentum 99.8%
*An isolate was considered well identified at the species level with a MALDI-TOF mass spectrometry score ≥ 1.9. **The API 50 CHL gallery is not designed to identify L.
zeae. ***Od.76 was formally identified as a L. zeae by sequencing the pheS gene (Genbank accession number: KJ402364).
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http://www.biomedcentral.com/1471-2180/14/107microbiota and commonly used as probiotics. Some of
them are used because of their positive effects on the
immune system, on the barrier effect of epithelia, whereas
others are used for their capacity to fight pathogens colon-
isation either via competitive exclusion or antimicrobial
molecules production. Probiotic effects are strain-specific,
consequently they do not possess the same activity and
they are not all recommended for the same health effects
[20]. Specific selection criteria are then needed in order to
find the right probiotic harbouring the appropriated activ-
ity (inhibition of pathogen for example) within a particular


























Figure 2 Growth of selected strains in artificial saliva. Bacterial conc
K.C6.3.1D (▲), K.C6.3.1E (●), K.V9.3.2B (■), K.V9.3.2C (♦), L. zeae Od.76 (◊)GG, L. plantarum 299, L. paracasei, L. casei, L. acidoph-
ilus), administered by oropharyngeal application or via
orogastric or nasogastric tube, have already been tested,
with different levels of success, in mechanically ventilated
patients to fight P. aeruginosa pneumonia [11,21]. To our
knowledge, none of them was specifically selected accord-
ing to its capacity to inhibit P. aeruginosa, nor to survive
in the oral cavity or in the oropharynx. The main goal
of this work was then to test the capacity of lactobacilli
isolated from oral cavities of healthy volunteers and
from raw milk to inhibit the production of virulence
factors by P. aeruginosa PAO1 in order to look for25 30 35 40 45 50
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Figure 3 Acidification of the artificial saliva during the growth of selected strains. Acidifying properties of L. fermentum ES.A.2 (Δ), ES.F.115 (○),
K.C6.3.1D (▲), K.C6.3.1E (●), K.V9.3.2B (■), K.V9.3.2C (♦), L. zeae Od.76 (◊) and L. paracasei ES.D.88 (□) in artificial saliva. Each value is the mean of
pH of three assays.
Alexandre et al. BMC Microbiology 2014, 14:107 Page 6 of 10
http://www.biomedcentral.com/1471-2180/14/107potential probiotic bacteria capable to prevent P. aeru-
ginosa pneumonia.
In this study, 67 isolates belonging to 9 Lactobacillus
species (L. reuteri, L. fermentum, L. vaginalis, L. rhamnosus,
L. zeae, L. paracasei, L. salivarius and L. plantarum), with
a prevalence of L. fermentum and L. paracasei, were recov-
ered from the oral cavities of 23 healthy volunteers. The
diversity of lactobacilli isolated from the oral cavity is gen-
erally high, and these 9 species are commonly encountered
in healthy persons [22-27]. Since it has been suggested that
oral lactobacilli may originate from the food [28], 20 Lacto-
bacillus strains (L. fermentum, L. brevis and L. parabuch-
neri) isolated from raw milk and whom certain species
have been previously described in the oral cavity were
added to increase the pool of the tested strains. Although
lactobacilli do not belong to the predominant oral micro-
biota, in which they account for less than 1% of the cultiv-
able fraction, they are suspected to have a considerable
effect on the homeostasis of this ecosystem [29].
Among the 87 tested isolates, the 10 most active ones
against P. aeruginosa virulence factors were identified at
the species level using a polyphasic approach combining
phenotypic (MALDI-TOF, API 50 CHL) and molecular
(16S rRNA and rpoA genes sequencing) methods, whereas
typing of L. fermentum strains was performed using PFGE.
Finally 8 strains (six L. fermentum, one L. paracasei
and one L. zeae) showed a significant inhibitory effect
against P. aeruginosa PAO1 biofilm formation or elas-
tolytic activity. With the exception of L. zeae and L.
paracasei that are facultative heterofermentative, all theactive strains belonged to the L. fermentum species and
were then obligate heterofermentative, producing both
lactic and acetic acids from glucose. It has been shown
that one of the major antibacterial effects of lactobacilli
is mediated via lactic and acetic acids production [15].
Indeed, lactobacilli may produce high concentrations of
lactic acid and acetic acid depending on their fermentative
pathways and growth conditions. We have shown that P.
aeruginosa PAO1 was sensitive to pH and acetic acid with
a dose-dependent effect, growth inhibition increasing in
parallel with an increase in acid concentration and pH de-
crease. At a pH of 4 or 5, acetic acid completely inhibited
the growth of P. aeruginosa at a concentration of 25 mM,
whereas high concentrations (≥50 mM) of acetic acid
were necessary to partially inhibit P. aeruginosa growth
at pH 6. For that reason, the inhibitory activities of lacto-
bacilli toward P. aeruginosa PAO1 biofilm formation and
elastolytic activity were not tested in MRS medium that
contains a high glucose concentration (20 g/L), but in BHI
medium. Indeed, this medium contains a low concentra-
tion of glucose (2 g/L) that limits the growth of Lactoba-
cillus strains and prevents a strong acidification, allowing
a better differentiation between the organic acids effects
from other mechanisms of action.
Elastolytic activity and biofilm formation are two ma-
jors virulence factors observed in P. aeruginosa. Among
the 8 strains (6 L. fermentum, one L. paracasei and one
L. zeae) significantly inhibiting elastase activity or bio-
film formation, it is interesting to note that the four L.
fermentum strains of milk origin (L. fermentum K.C6.3.1D,
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activity only, whereas the ones originating from the oral
cavity (L. fermentum ES.A2, ES.F.115) inhibited biofilm
formation only. The two other active strains from the oral
cavity, L. zeae Od.76 and L. paracasei ES.D.88 significantly
inhibited elastase activity and biofilm formation respect-
ively. Elastase has been shown to destroy respiratory epi-
thelium tight junctions, increasing permeability disorders
and interleukin-8 levels while decreasing host immune re-
sponse [30,31]. We previously showed in a murine model
of P. aeruginosa pneumonia, that elastolytic activity was
positively correlated to acute lung injury [5]. It has been
shown by Rumbaugh et al. that elastolytic activity and bio-
film formation are under control of the quorum sensing
molecules of P. aeruginosa [32]. Different mechanisms of
action may then be hypothesized, active Lactobacillus
strains inhibited the quorum sensing targets, either they
secreted antagonistic analogues of acyl-homoserine lactone
or they inhibited regulating lasR or lasI genes factors [33].
Moreover, the use of the BHI medium that induced a lim-
ited pH decrease, together with the low number of active
strains, suggested that other mechanisms of action than
organic acids production were implicated. It has been
shown that surface properties, such as cell charge and
hydrophobicity, implicated in the non-specific adhesive
capacity of bacteria differ among Lactobacillus strains
isolated from the oral cavity of healthy volunteers, with
several strains (including strains of L. fermentum and L.
paracasei) showing very high adhesive properties [23].
Such a difference in surface properties between lactobacilli
strains with a prevalence of high adhesive properties in
lactobacilli strains isolated from the mouth might be impli-
cated in their higher capacity to prevent biofilm formation
as compared to dairy lactobacilli. Indeed surface properties
are involved in adhesion properties to plastic and/or
in the co-aggregation with P. aeruginosa that could be
implicated in decreasing biofilm formation. However,
further studies are needed to elucidate the antagonistic
mechanism of action between described lactobacilli strains
and P. aeruginosa.
Antagonistic activities of probiotic bacteria require a
certain capacity to survive and/or to grow in the tar-
geted ecosystem. All active strains showed a good cap-
acity to grow in artificial saliva, suggesting that they may
survive in the oral environment. However, it has been
suggested that some probiotics may be implicated in the
development of dental caries [34]. The use of poorly
acidifying strains such as L. fermentum K.V9.3.2B and K.
V9.3.2C inhibiting elastolytic activity and L. fermentum
ES.F.115 and ES.A.2 inhibiting biofilm formation may
then be encouraged in their use as probiotics to fight P.
aeruginosa pulmonary infection compared to the more
acidifying ones. However, knowing that acid production
strongly inhibits P. aeruginosa growth, the use of moreacidifying strains may be also investigated and subjected
to an appropriate follow-up of dental health during pro-
biotic application. Another theoretical concern regarding
the safety of probiotics is the transfer of antibiotic resist-
ance genes toward the oral and gastrointestinal micro-
biota. In our study, as expected for lactobacilli that are
intrinsically resistant to vancomycin, all the strains were
resistant to vancomycin [35]. No other resistance to-
wards the recommended antibiotics was detected. On
the other hand the toxic effect of putative probiotic on
the epithelial cells from the oropharynx and respiratory
tract will have to be investigated.
Conclusions
The pathogenesis of ventilator acquired pneumonia re-
quires micro-aspiration of oropharynx microbiota into
the lower airway. The natural oropharynx microbiota of
patients is modified by exogenous bacteria from the
hands of the health care workers for example or by en-
dogenous bacteria such as the intestinal microbiota by
retrograde contamination. In our study, we screened 87
lactobacilli isolates from the oral cavity of healthy people
and from milk with the aim to prevent P. aeruginosa
from colonising the oropharynx environment. Eight strains,
devoid of acquired antibiotic resistance were able to grow
in artificial saliva and to decrease two virulence factors
(elastolytic activity and biofilm formation) of P. aeruginosa
in vitro. The next step will be to check if these strains in-




Lactobacilli from swab samples belong to the biological
collection DC-2008-214 of Brest University Hospital.
This biological collection was approved by Ministry of
Higher Education and Research. Our study was approved
by our Medical Hospital University ethics committee
(« Comité de Protection des Personnes Ouest VI »). A
written informed consent was obtained from all healthy
adults volunteers participating in the study for publication
of this case report. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
There were no under age children (<18 years-old) in-
cluded in our study.
Bacterial strains and culture conditions
P. aeruginosa PAO1, initially isolated from an infected
wound [36], was chosen as reference strain for the activ-
ity tests. It was routinely cultivated overnight at 37°C in
Luria Bertani (LB), or in Brain Heart Infusion broth
(BHI) prior to the activity experiments. A total of 87
Lactobacillus isolates were tested for their capacity
to inhibit P. aeruginosa PAO1 biofilm formation and
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tion of Lactobacillus spp. (15 L. fermentum, 1 L. brevis and
4 L. parabuchneri) previously isolated from raw milks in
our laboratory [13], and 67 were isolated from the mouth
of healthy volunteers during this work (see below). Lacto-
bacillus fermentum ATCC 9338 was obtained from AES
Chemunex (Bruz, France), whereas Lactobacillus casei
LMG 6904 and Lactobacillus paracasei LMG 13087 were
obtained from the BCCM/LMG Bacteria Collection
(http://bccm.belspo.be/about/lmg.php). They were used as
reference strains for lactobacilli identification. Lactobacilli
were cultured in de Mann, Rogosa and Sharpe (MRS)
broth at 37°C. All strains were maintained as 33% glycerol
stock at −80°C. All bacterial growth media were pur-
chased from AES Chemunex, Bruz, France if not other-
wise stated.
Isolation and identification of oral lactobacilli
Twenty-three healthy adult volunteers were asked to rub
the inside of their mouth with sterile swabs, which were
then used to inoculate LAMVAB, a selective agar medium
for the isolation of lactobacilli [37]. After 48 h of incuba-
tion at 37°C, single colonies were picked-up and trans-
planted at least thrice on MRS agar for isolation.
Isolates were examined by phase-contrast microscopy,
Gram stained and tested for the absence of catalase.
They were then assigned to the Lactobacillus genus by
MALDI-TOF mass spectrometry analyses with protein
extraction [13]. Once several isolates were described as
effective against P. aeruginosa PAO1, they were formally
identified by sequencing their 16S rRNA, rpoA and pheS
genes, using respectively U1/RU2, rpoA-21-F/rpoA-23-R
and pheS-21-F/pheS-22-R primers on their total DNA
[38,39]. Part of the 16S rRNA gene was amplified with an
initial denaturation step performed for 15 min at 95°C,
followed by 30 amplifications cycles consisting of 1 min at
95°C for denaturation, 30s at 64°C for primer annealing,
1 min at 72°C for extension, and one final extension of
5 min at 72°C. For the rpoA and pheS genes, an initial de-
naturation step was performed for 5 min at 95°C, followed
by 3 amplification cycles of 1 min at 95°C, 2 min 15 s at
46°C, 1 min 15 s at 72°C, and 30 cycles of 35 s at 95°C,
1 min 15 s at 46°C, 1 min 15 s at 72°C and a final exten-
sion step of 7 min at 72°C. In few cases, an annealing
temperature of 42°C was used for the amplification of
rpoA or pheS. PCR amplicons were sequenced either at
the molecular genetic department sequencing platform
in the “CHRU de Brest” (INSERM-U1078) or at the
Biogenouest platform (Roscoff, France). Sequences were
then assembled using DNA Baser 3.5.3, and aligned using
the MAFFT tool (http://mafft.cbrc.jp/alignment/server/)
(December 2012) for species assignment. Phylogenetic
analyses were conducted by the neighbour-joining method
using MEGA 5.05/5.10 software [40]. Bacterial sequencesfor the sequenced strains have been deposited in GenBank
and accession numbers are available in Table 4. Bio-
chemical profiles were analysed by using API 50 CHL
test kit (Biomérieux, Marcy l’Étoile, France). Isolates
belonging to the L. fermentum species were then typed
with PFGE analyses as described by Delavenne et al. [41].Effects of pH and organic acids on P. aeruginosa PAO1
growth
An overnight culture of P. aeruginosa PAO1 was har-
vested by centrifugation, washed, and suspended in the
same volume of saline solution (NaCl 0.9%). One hun-
dred microliters of this suspension was then used to in-
oculate 10 ml of LB supplemented with acetic acid (50
or 100 mM) or lactic acid (12.5, 25, 50 or 100 mM) at
different pH (4, 5, 6 and 7). The growth of P. aeruginosa
PAO1 was monitored by measuring the OD600nm after
22 h of incubation at 37°C. Negative controls consisted
in culturing P. aeruginosa PAO1 with no acetic or lactic
acids but with hydrochloric acid (HCl) in order to reach
the desired pH. All the tests were performed in triplicate.Inhibition of P. aeruginosa biofilm formation
The capacity of Lactobacillus isolates to inhibit biofilm
formation by P. aeruginosa PAO1 was tested with a
colorimetric method adapted from Merrit and Valdez
[42,43]. P. aeruginosa PAO1 and lactobacilli were culti-
vated overnight at 37°C separately in BHI broths. After
incubation, the two bacterial suspensions were washed
with a saline solution, diluted in BHI (pH 7.4), and
mixed in order to obtain a final suspension containing
5 × 107 CFU/ml of P. aeruginosa and 5 × 107 CFU/ml of
the tested Lactobacillus isolate. One hundred millilitres
of this bacterial suspension was deposited per well in
96-well flat-bottomed microplates (Corning Incorpo-
rated, Corning, USA), that were incubated at 37°C. After
7 h, the wells were washed twice with a saline solution
(NaCl 0.9%), and 100 μl of crystal violet (0.25%) were
added in each well for biofilm colouring. After 10 min,
wells were washed twice again with the saline solution
and the remaining crystal violet was released by addition
of 100 μl of acetic acid (33%). Finally, the acetic acid
solution containing the released crystal violet was trans-
ferred in a new microplate and the OD595nm was measured
using a spectrophotometer (Multiskan FC Microplate
Photometer, Thermo Scientific, Waltham USA). The posi-
tive control was the amount of biofilm formed with a pure
culture of P. aeruginosa PAO1, whereas the negative
control was sterile BHI. Three series of four wells were
performed. In parallel, the viability of P. aeruginosa on
co-cultures with lactobacilli during 7 hours was evaluated
by plate counts. Acidification was quantified through pH
measurement.
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The capacity of Lactobacillus isolates to inhibit the elasto-
lytic activity of P. aeruginosa PAO1 was tested with a col-
orimetric method adapted from Rust et al. [44]. Aliquots
(2 ml) of bacterial suspensions (P. aeruginosa PAO1 at
5 × 107 CFU/ml and Lactobacillus isolate at 5 × 107 CFU/
ml) used for the biofilm experiment were also used in the
elastase assay. They were incubated at 37°C for 22 h, cen-
trifuged at 2 000 × g for 5 min, and one ml of a solution of
elastin Congo-red (20 mg/ml; Sigma-Aldrich, St Louis,
USA) in a 10 mM sodium phosphate buffer (pH 7.0) was
added to the supernatant that was incubated at 37°C for
18 h. The insoluble elastin Congo-red was pelleted at 2
000 × g for 20 min and the absorbance of the Congo-red
soluble fraction released by elastase, was measured at
450 nm with a spectrophotometer (Multiskan* FC Micro-
plate Photometer, Thermo Scientific). The positive control
was the elastolytic activity in a pure culture of P. aerugi-
nosa PAO1 and the negative control was sterile BHI.
Three series of experiments were performed. The viability
of P. aeruginosa on co-cultures with lactobacilli during
22 hours was evaluated by plate counts. Acidification was
quantified through pH measurement.
Sensitivity of lactobacilli to antibiotics
Lactobacillus isolates were tested for their susceptibility to
a panel of 10 antibiotics (ampicillin, vancomycin, gentami-
cin, kanamycin, streptomycin, erythromycin, clindamycin,
quinupristin + dalfopristin, tetracycline, chloramphenicol).
The screening was performed with Etests (Etest®, Bio-
mérieux, Marcy l’Étoile, France) following instructions
as indicated by the producer. Lactobacilli were cultivated
on MRS agar during 48 h, colonies were picked-up and
suspended in 5 ml of a saline solution (0.9% NaCl) to
obtain a McFarland standard OD of 0.5, and five drops of
this suspension were added to 10 ml of a new saline so-
lution. The suspension was finally spread on blood agar
plates (AES Chemunex, Bruz, France), the excess liquid
was discarded, and the Etests stripes were applied to
the dried plates. The minimal inhibition concentrations
(MIC), expressed in mg/L, were read on the Etest stripes
after 48 h of incubation at 37°C. Results were interpreted
according to the cut-off levels proposed for Enterococcus
spp. by the Committee of the antibiogram of the French
society for microbiology [41,45].
Lactobacilli growth and acidification properties in
artificial saliva
The growth in artificial saliva of several Lactobacillus
strains (L. zeae Od.76, L. paracasei ES.D.88 and L. fer-
mentum ES.A.2, ES.F.115, K.C6.3.1D and K.V9.3.2C) was
regularly monitored by determining the pH and plate
counts on MRS agar during 48 h of incubation at 37°C.
Artificial saliva composition was previously described byRoger et al. [46]. Initial concentrations of tested isolates
were set around 5 log10 CFU/ml. All experiments were
carried out in triplicate.
Statistics
Statistical analyses were performed using the Microsoft
Excel 2010 (Microsoft Corporation, Redmond, USA) and
SAS 9.3 (SAS Institute Inc., Cary, USA) software products.
In order to test the significance of the elastolytic activity
and biofilm formation assays, the correlation between the
three series of experiments was first assessed by the
Student's inverse test (p < 0.05). Once the correlation be-
tween the assays was established, significant differences
within each assay were carried out with a one-way analysis
of variance (ANOVA), and the least significant difference
(LSD) test was used to detect antagonistic activities of
lactobacilli strains against Pseudomonas aeruginosa. Stat-
istical significance were set at a p = 0.001 for elastolytic
activity and p = 0.05 for biofilm formation. Organic acids
and pH effects on P. aeruginosa PAO1 growth were
studied by performing covariance analyses (ANCOVA)
on optical densities.
Additional file
Additional file 1: Fermentation patterns of active strains. This table
presents the whole results obtained with the API 50 CHL gallery for the 8
tested strains.
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